Company news

Corcept Therapeutics Incorporated news in 2026

Corcept Therapeutics Incorporated's news releases, calls and decks from 2026, newest first.

View company

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 27, 2026

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

October 26, 2026

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

October 20, 2026

Corcept Announces Planned Leadership Transition

September 23, 2026

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

September 18, 2026

Corton Capital Inc. Announces Launch of Corton Rosenberg Global Macro Fund

September 9, 2026

CORRECTION FROM SOURCE: Corton Capital Inc. Announces August 2026 Distributions for the Exchange Traded Fund

August 25, 2026

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

June 17, 2026

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

June 6, 2026

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

May 27, 2026

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

April 30, 2026

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

April 21, 2026

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

April 9, 2026

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

March 27, 2026

Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)

March 26, 2026

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

March 24, 2026

Alger Russell Innovation Index Updates for First Quarter 2026

March 16, 2026

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

February 24, 2026

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

February 18, 2026

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

February 17, 2026

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

January 21, 2026

Calls in 2026

Decks in 2026